HSK39004 Dry Powder Inhaler -0.75mg BID + HSK39004 Dry Powder Inhaler -1.5mg BID + HSK39004 Inhalation Suspension -3mg BID + HSK39004 Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Obstructive Lung Disease (COLD)
Conditions
Chronic Obstructive Lung Disease (COLD)
Trial Timeline
Apr 24, 2025 → Aug 1, 2025
NCT ID
NCT07140328About HSK39004 Dry Powder Inhaler -0.75mg BID + HSK39004 Dry Powder Inhaler -1.5mg BID + HSK39004 Inhalation Suspension -3mg BID + HSK39004 Placebo
HSK39004 Dry Powder Inhaler -0.75mg BID + HSK39004 Dry Powder Inhaler -1.5mg BID + HSK39004 Inhalation Suspension -3mg BID + HSK39004 Placebo is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Chronic Obstructive Lung Disease (COLD). The current trial status is active. This product is registered under clinical trial identifier NCT07140328. Target conditions include Chronic Obstructive Lung Disease (COLD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07140328 | Phase 2 | Active |
Competing Products
20 competing products in Chronic Obstructive Lung Disease (COLD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |